ATS 2021

We are pleased to share details on the presentations and new data that will be presented at ATS 2021. 

Attending ATS 2021?

Registered attendees, please visit our booth in the virtual exhibit hall to learn more.

Visit Virtual Booth


Old Habits Die Hard; Managing Lung Nodules with Size Alone Is Not Sufficient

Author: S. C. Springmeyer1, J. R. Jett2Medical, Biodesix, Boulder, CO, United States, National Jewish Health, Denver, CO, United States

View Abstract


Nodify Lung™ testing consists of two blood-based proteomic tests (the Nodify CDT™ & Nodify XL2® tests) to help physicians reclassify risk of cancer and aid in stratifying patients into distinct nodule management pathways: intervention or surveillance.


Learn More

Biodesix Lung Color Logo

Biodesix Lung Reflex® testing consists of the GeneStrat® tumor profiling test and the VeriStrat® immune profiling test to provide physicians with timely molecular results to facilitate treatment decisions for patients with non-small cell lung cancer.


Learn More

We provide biopharmaceutical companies with end-to-end diagnostic services inclusive of diagnostic research and feasibility, assay development, clinical trial testing, and commercialization of companion diagnostics.


Learn More

Not attending ATS 2021?

Fill out the form below to be notified when the poster is available.


Contact us with any questions